The expression of death receptor 6 (DR6) is abnormal in some cancer types, but the function and underlying molecular mechanisms of DR6 in tumor progression are not yet clear. In the present study, our analysis of ovarian cancer RNA sequencing data from The Cancer Genome Atlas revealed that DR6 is upregulated in human ovarian cancer. We confirmed that the expression level of DR6 is upregulated in ovarian cancer tissues when compared with matched adjacent normal tissues. In addition, DR6 enhanced ovarian carcinoma cell migration ability, and decreased expression of DR6 inhibited the expression of matrix metalloprotease (MMP) 2 and MMP9, and increased the expression of E-cadherin. Additionally, DR6 shRNA caused a significant decrease in phosphoinositide-3-kinase (PI3K), phospho (p)-AKT, p-extracellular signal-regulated kinase (ERK), and p-mitogen-activated protein kinase kinase expression in SKOV3 cells. These results suggested that DR6 can enhance ovarian carcinoma cell migration ability through the mitogen-activated protein kinase/ERK and PI3K/AKT pathways. Notably, mass spectrometric analysis indicated that DR6 co-purified with kinesin family member 11 (KIF11), and we verified the interaction between KIF11 and DR6 by co-immunoprecipitation and glutathione S-transferase pull-down. Furthermore, we demonstrated that DR6 can bind tumor necrosis factor receptor-associated factor 4 (TRAF4) with co-immunoprecipitation. Overexpression of KIF11 or TRAF4 eliminated the suppression of carcinoma cell migration by DR6 knockdown. We also found that TRAF4 and KIF11 were upregulated in ovarian carcinomas and that their level of expression was positively correlated with that of DR6. The findings above suggest that DR6 may play a notable oncogenic role in ovarian malignancy by interacting with TRAF4 and KIF11, and that DR6 may be an effective therapeutic target in ovarian cancer.

Death receptor 6 (DR6) is a member of the tumor necrosis factor (TNF) receptor superfamily [1]. The specific ligands activate death receptors to mediate diverse biological processes, including cell apoptosis and immune response [2–4]. In the neuronal system, brain vascular formation is suppressed in DR6−/− mice
and in zebrafish [5], and DR6 deficiency has been identified as promoting remyelination in a demyelination model [6].

As a death receptor, DR6 is reported to be involved in apoptotic cell death. The cleaved N-terminal fragment of β-amyloid precursor protein binds to DR6 to trigger axon pruning and neuron death via caspase 6 in the central nervous system [7], while the antagonist antibody of DR6 promotes motor neuron survival [8]. DR6 can bind TNF receptor-associated death domain protein (TRADD) when overexpressed [1]. Furthermore, the agonistic antibody for DR6 activates downstream signaling involved in the recruitment of TRADD [9].

DR6 is highly expressed in certain cancer types; however, less is known about its role in tumor progression. Thus, the function of DR6 in cancer needs to be clarified. The expression of anti-apoptosis molecules is elevated due to DR6 overexpression in certain cancer cells [10]. It has been found that the expression of DR6 in serum is enhanced in patients with late-stage ovarian cancer (OVCA) [11]. Additionally, tumor-cell-induced endothelial cell necroptosis occurs via DR6 [12]; however, the function of DR6 in cancer cells, particularly in OVCA, still requires investigation. To this end, in the current study, we report that DR6 plays a vital oncogenic role in promoting ovarian cell migration by interacting with kinesin family member 11 (KIF11) and TNF receptor-associated factor 4 (TRAF4), and that DR6 may be an effective therapeutic target in OVCA.

Materials and methods

Cell lines and reagents

Cell Culture Center, Chinese Academy of Medical Sciences (Beijing, China) provided the OVCA cell lines SKOV3, HO-8910, A2780 and OVCAR3. Cells were maintained at 37°C with 5% CO2 in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS; Invitrogen). Cells were transiently transfected with plasmid or small interfering RNAs (siRNAs) against KIF11 or TRAF4 (Table 1, GenePharma, Shanghai, China) using Lipofectamine® 2000 (Invitrogen) according to the manufacturer’s instructions. Target proteins expression was checked by western blotting at 48 h after transfection.

Patients and specimens

The First Affiliated Hospital of Harbin Medical University provided the fresh OVCA tissues and normal ovarian epithelial tissue. Patients provided informed consent. Institutional Review Board of Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences approved the current study. The classifications of cancer stage and grade were made according to the International Federation of Gynecology and Obstetrics criteria [13].

Reverse transcription-quantitative PCR

TRIzol (Invitrogen) was used to purify total RNA according to the manufacturer’s protocol. The cDNA was obtained from RNA by using M-MLV Reverse Transcriptase (Promega, Madison, WI, USA). The expression of target RNAs was measured by qPCR with SYBR Green PCR Master Mix (Thermo Fisher Scientific, Waltham, MA, USA) on a StepOnePlus system (Applied Biosystems). Sangon Biotech (Shanghai, China) produced the primers, which were designed using Primer Premier 5.0. The thermocycling conditions for qPCR included initial denaturation (5 min at 95°C), followed by 40 cycles (15 s at 95°C, 30 s at 60°C, and 30 s at 72°C) and extension (7 min at 72°C). The relative gene expression was calculated using the $2^{-\Delta\Delta CT}$ method, and the internal control was glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The primer sequences are shown in Table 1.

Western blot analysis

Total protein was obtained after cells were lysed using M-PER Mammalian Protein Extraction Reagent (Thermo Fisher Scientific) with protease inhibitor cocktail (Sigma, St Louis, MO, USA). After the protein was denatured, equal amounts of protein were loaded in each lane for SDS/PAGE, and then, the protein was transferred onto PVDF membranes. The membranes were blocked using Tris-buffered saline (10 mM Tris, 150 mM NaCl) with 0.05% Tween 20 (TBST) with 5% nonfat milk for 120 min, then incubated separately with primary antibodies against matrix metalloprotease (MMP) 2 (polyclonal, rabbit anti-human, cat. no. 4022), MMP9 (polyclonal, rabbit anti-human, cat. no. 3852), E-cadherin (monoclonal, rabbit anti-human, cat. no. 8834), phosphoinositide-3-kinase (PI3K; polyclonal, rabbit anti-human, cat. no. 3811), AKT (polyclonal, rabbit anti-human, cat. no. 9272), phospho-(p)-AKT (monoclonal, rabbit anti-human, cat. no. 5012), mitogen-activated protein kinase kinase (MEK) 2 (polyclonal, rabbit anti-human, cat. no. 9154), extracellular signal-regulated kinase (ERK; polyclonal, rabbit anti-human, cat. no. 4694), p-ERK (monoclonal, rabbit anti-human, cat. no. 8544), KIF11 (monoclonal, rabbit anti-human, cat. no. 14404), and TRAF4 (monoclonal, rabbit anti-human, cat. no. 18527). The antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA; all 1:1000). Additionally, incubation with primary antibody against DR6 (monoclonal, rabbit anti-human, cat. no. 3216R-100; Biovision, Milpitas, CA, USA; 1:1000) and FLAG (monoclonal, mouse anti-human, cat. no. M185-3L; MBL, Nagoya,
Table 1. Primers and siRNA sequence.

| Primer and siRNA sequence | Sequence |
|---------------------------|----------|
| GAPDH forward             | 5′-CGGATTTGGTCTGATTTGG-3′ |
| GAPDH reverse             | 5′-CTGGAAGATGTTGATGGATT-3′ |
| DR6 forward               | 5′-ATCCGAGAAAGCTCTGAGGAC-3′ |
| DR6 reverse               | 5′-CTTCCCCTGGGCTGCTAC-3′ |
| KIF11 forward             | 5′-GCCCAAATGGAAGCATTT-3′ |
| KIF11 reverse             | 5′-CTTCTGGGTAGATCTTGGCATAG-3′ |
| TRAF4 forward             | 5′-CAACCGGAACTTGAGAAT-3′ |
| TRAF4 reverse             | 5′-CAACCGGAACTTGAGAAT-3′ |
| shDR6-1 forward           | 5′-CAACCGGAACTTGAGAAT-3′ |
| shDR6-1 reverse           | 5′-CAACCGGAACTTGAGAAT-3′ |
| shDR6-2 forward           | 5′-CAACCGGAACTTGAGAAT-3′ |
| shDR6-2 reverse           | 5′-CAACCGGAACTTGAGAAT-3′ |
| DR6 signal peptide forward| 5′-CTTCTTTTGAGTGGTCTTCTG-3′ |
| DR6 signal peptide reverse| 5′-CTTCTTTTGAGTGGTCTTCTG-3′ |
| Fusion sequence (DR6 signal peptide and 3×flag) forward| 5′-CTTCTTTTGAGTGGTCTTCTG-3′ |
| Fusion sequence (DR6 signal peptide and 3×flag) reverse| 5′-CTTCTTTTGAGTGGTCTTCTG-3′ |
| Fusion sequence (DR6 signal peptide and 3×flag and DR6) forward| 5′-CTTCTTTTGAGTGGTCTTCTG-3′ |
| Fusion sequence (DR6 signal peptide and 3×flag and DR6) reverse| 5′-CTTCTTTTGAGTGGTCTTCTG-3′ |
| KIF11 siRNA sense         | 5′-AGGAGAAGGACACTGATTCAGG-3′ |
| KIF11 siRNA antisense     | 5′-AGGAGAAGGACACTGATTCAGG-3′ |
| TRAF4 siRNA sense         | 5′-CTTCTTTTGAGTGGTCTTCTG-3′ |
| TRAF4 siRNA antisense     | 5′-CTTCTTTTGAGTGGTCTTCTG-3′ |

GAPDH, glyceraldehyde-3-phosphate dehydrogenase; KIF11, kinesin family member 11; shDR6-1, short hairpin DR6-1; shDR6-2, short hairpin DR6-2; TRAF4, TNF receptor-associated factor 4.

Japan; 1 : 500) dissolved in 5% nonfat milk in TBST overnight at 4 °C was performed separately. Human GAPDH antibody (monoclonal, mouse anti-human, cat. no. KC-5G4; KangChen Biotech, Shanghai, China; 1 : 5000) was used as an internal reference. Immunoblots were quantified using IMAGEJ software (developed by National Institutes of Health, Bethesda, MD, USA).

Plasmid generation

The full-length KIF11 or TRAF4 cDNA sequence was amplified from the total RNA of SKOV3 cells by RT-PCR using the primers listed in Table 1 and inserted at EcoRI/XhoI sites of the pcDNA3.1(+) to generate pcDNA3.1-KIF11 and pcDNA3.1-TRAF4 overexpression plasmid.

Lentivirus infection and construction of stable DR6-knockdown cell lines

Short hairpin RNAs (shRNAs) targeting DR6 were inserted into pLL3.7 vectors. The targeting sequences are listed in Table 1. Lentiviruses were obtained by cotransfecting the recombinant pLL3.7 vectors and psR5-Rev, pMDLg/pRRE, and pMD2.G packaging vectors. Lentiviruses with infection were obtained at 48 and 72 h after transfection. The viruses were filtered with 0.45 μm porous membranes (Corning Inc., Corning, NY, USA) were used for motility assays. Approximately 2 × 10^5 cells without FBS were used as an internal reference. Immunoblots were quantified using IMAGEJ software (developed by National Institutes of Health, Bethesda, MD, USA).

Cancer cell migration assay

Transwell insert chambers with 8-μm porous membranes (Corning Inc., Corning, NY, USA) were used for motility assays. Approximately 2 × 10^5 cells without FBS were used as an internal reference. Immunoblots were quantified using IMAGEJ software (developed by National Institutes of Health, Bethesda, MD, USA).

Lentiviruses were obtained by cotransfecting the recombinant pLL3.7 vectors and psR5-Rev, pMDLg/pRRE, and pMD2.G packaging vectors. Lentiviruses with infection were obtained at 48 and 72 h after transfection. The viruses were filtered with 0.45 μm porous membranes (Corning Inc., Corning, NY, USA) were used for motility assays. Approximately 2 × 10^5 cells without FBS were used as an internal reference. Immunoblots were quantified using IMAGEJ software (developed by National Institutes of Health, Bethesda, MD, USA).
added to the upper chamber, and medium with 10% FBS was added to the lower chamber. The cells were cultured for 24 h. The cells on the upper surface of the upper chamber were scraped off using a cotton bud, and the chamber was rinsed with phosphate buffer. Then, the cells on the lower surface of the chamber were soaked in 4% paraformaldehyde. Once the surface was dry, the cells were dyed with 1% crystal violet for 2 min. The migrating cells were those on the lower surface of the chamber. Migrating cells were counted at ×100 or ×200 magnification in eight fields of view.

**Immunofluorescence experiments**

The cells were washed with phosphate buffer and fixed with 4% paraformaldehyde for 20 min. Then, the cells were incubated for 10 min with 0.2% Triton X-100 to change the permeability and washed three times with 0.01 M phosphate buffer (5 min per wash). Next, the cells were soaked in 1% BSA at 37 °C for 20 min and then incubated separately with primary antibody [anti-FLAG (monoclonal, mouse anti-human, cat. no. M185-3L; MBL; 1 : 500) and anti-KIF11 (monoclonal, rabbit anti-human, cat. no. 14404; Cell Signaling Technology; 1 : 500)] diluted with 1% BSA, at room temperature for 1 h. The cells were incubated separately with secondary antibody (Cell Signaling Technology, cat. no. 8890, cat. no. 4412; 1 : 200) and Hoechst (1 : 200) for 1 h after being washed with 0.05% Tween-20. Next, the cells were washed three times with 0.05% Tween-20 (5 min per wash), then with 0.01 M phosphate buffer for 5 min. The cells were observed under a fluorescence microscope.

**Immunoprecipitation**

The signal peptide of DR6, 3×Flag, and DR6 sequences was fused by PCR. The primers are listed in Table 1. The fused sequence was cloned into pcDNA3.1. HEK293T cells were transiently transfected with pcDNA3.1-Flag-DR6 using Lipofectamine 2000 according to the manufacturer’s instructions. Then, DR6 expression was checked by western blotting at 48 h after transfection. When the immunoprecipitation experiment was performed, the cells transfected with pcDNA3.1-FLAG-DR6 in 10-cm culture dishes were collected and washed three times with phosphate buffer. The cells were subjected to a 30-min lysis with buffer (pH 7.5, 150 mM NaCl, 20 mM Tris/HCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA) including protease inhibitors (Roche, Indianapolis, IN, USA). The mixture was centrifuged at 13 000 g for 30 min at 4 °C and then used for immunoprecipitation (IP) with FLAG antibody or DR6 antibody for 8 h on ice. Then, protein A agarose beads were added to the mixture and shaken for 6 h at 4 °C. The immunoprecipitates were washed five times with phosphate buffer. The mixture was used for SDS/PAGE (5% acrylamide for the spacer gel and 12% acrylamide for the separation gel). Then, the proteins were silver stained or transferred to a PVDF membrane, which was subjected to chemiluminescence and exposure.

**Glutathione S-transferase pull-down**

Approximately 600 μg lysates of HEK-293T cells (Cell Culture Center, Chinese Academy of Medical Sciences, Beijing, China) transfected with Flag-DR6 were used for glutathione S-transferase (GST) pull-down assay in vitro. The lysis buffer was composed of 50 mM Tris/HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 1 mM EDTA, and protease inhibitor cocktail. The lysates were blended with 6 μg of GST–KIF11 or GST. These mixtures were combined with glutathione/Sepharose beads for 4 h at 4 °C and washed 10 times with buffer. The mixtures were run on 12% SDS/PAGE and then incubated with anti-FLAG (monoclonal, mouse anti-human, cat. no. M185-3L; MBL; 1 : 200) and anti-GST antibodies (monoclonal, mouse anti-human, cat. no. 2625, Cell Signaling Technology; 1 : 200) separately. The antibodies were diluted with 1% BSA.

**Statistical analysis**

Statistical analysis was performed using sspss version 17.0 software (SPSS, Inc., Chicago, IL, USA). One-way ANOVA and Student’s t test were used for data analysis. Two-sided P < 0.05 was considered to indicate a statistically significant difference.

**Results**

**Death receptor 6 is upregulated in OVCA**

On analysis of The Cancer Genome Atlas (TCGA) OVCA and normal tissue RNA sequencing data (http://gepia.cancer-pku.cn/index.html) [14], the expression level of DR6 was higher in OVCA than in normal tissues (Fig. 1A). We subsequently analyzed the expression level of DR6 in OVCA cells by western blot analysis. As shown in Fig. 1B, compared with normal human ovarian surface epithelial (HOSE) cells, DR6 was significantly upregulated in the four OVCA cell lines (SKOV3, HO-8910, A2780, and OVCAR3). Total RNA and protein were isolated from OVCA tissues and from matched adjacent normal tissues to detect the expression level of DR6. The expression of DR6 was analyzed by quantitative PCR and western blot. The results indicated that the mRNA and protein expression levels of DR6 were higher in OVCA samples than they were in the matched adjacent normal samples (Fig. 1C,D).
It was shown that among the OVCA cells assessed, DR6 expression was highest in SKOV3 cells (Fig. 1B). Thus, in subsequent assays, the roles of DR6 were investigated in SKOV3 cells. To study the potential role of DR6 in cell growth, the proliferation of SKOV3 cell lines transfected with DR6 shRNA vectors was analyzed by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. As shown in Fig. 2A, DR6 shRNA induced a corresponding down-regulation in DR6. The MTS assays showed that DR6 knockdown did not change the viability of OVCA cells (Fig. 2B). Next, a transwell assay was performed to detect cell migration ability following the knockdown of DR6 in SKOV3 cells. After transfection with shRNA to decrease endogenous DR6 expression, the migration of the SKOV3 cells was markedly reduced (Fig. 2C). Furthermore, the migration-associated protein expression in SKOV3 cells was examined by western blot analysis. The results indicated that when the expression of DR6 was inhibited, the expression of MMP2 and MMP9 was inhibited, but the expression of E-cadherin was enhanced (Fig. 2D).

The PI3K/AKT and mitogen-activated protein kinase (MAPK)/ERK signaling pathways have been widely reported to be among the most important signaling pathways that participate in a regulatory network during cell migration in various cancers [15–17]. The expression level of PI3K, p-AKT, p-MEK, and p-ERK was evaluated by western blot analysis. The results showed that DR6 shRNA led to an obvious decrease in PI3K, p-AKT, p-MEK, and p-ERK expression in SKOV3 cells, compared with the vector control groups. This finding indicated that the activation of the PI3K/AKT or MAPK/ERK pathway might participate in the effect of DR6 on OVCA cell migration (Fig. 2E).

Identification of DR6-interacting proteins by coimmunoprecipitation–mass spectrometry

To confirm the molecular mechanism of DR6 in OVCA migration, we used the co-IP–mass spectrometry (MS) method to find DR6-interacting proteins in HEK-293T cells. Cells expressing Flag-DR6 recombinant protein and cells expressing Flag-GFP recombinant protein were cultured. Flag-DR6 expression was identified by Flag antibody (Fig. 3A). Flag agarose purified cellular lysate, and the mixture (including anti-Flag antibody, Flag-DR6 and interaction protein with DR6) obtained was run on an SDS/PAGE gel and stained with silver (Fig. 3B). DR6 co-purified with several proteins by MS analysis, among which the content of KIF11 was highest. To confirm the interaction
between KIF11 and DR6, total protein from SKOV3 cells transfected Flag-DR6 was extracted, and co-IP experiments were performed with FLAG antibodies against proteins. IP with an antibody against FLAG followed by immunoblotting (IB) with an antibody against KIF11 demonstrated that DR6 co-immunoprecipitated with KIF11 (Fig. 3C). Furthermore, we found that DR6 and KIF11 could interact directly in a GST pull-down assay (Fig. 3D). DR6 and KIF11 also localized together on the cytomembrane of HEK-293T and SKOV3 cells when analyzed by immunofluorescence (Fig. 3E,F). It was reported that TRAF4 was identified as an interacting protein of KIF11 in a previous MS analysis [18]. Therefore, we subsequently tested whether DR6 could bind TRAF4 using co-IP. As shown in Fig. 3G, IP with an antibody against DR6 and IB with antibodies against TRAF4 and KIF11 revealed that TRAF4 and KIF11 co-immunoprecipitated with DR6 simultaneously.

**DR6 functions through its association with KIF11 and TRAF4**

Whether the function of DR6 was based on the association of DR6 with KIF11 and TRAF4 was evaluated using KIF11 or TRAF4 overexpression (Fig. S1) in SKOV3 cells. As shown in Fig. 4A, the overexpression of KIF11 or TRAF4 promoted SKOV3 cell migration. Next, using a rescue experiment, we evaluated whether the DR6-mediated promotion of SKOV3 cell migration depended on its association with KIF11 and TRAF4. As shown in Fig. 4A, the inhibition of cell migration ability in the DR6-knockdown SKOV3 cells was rescued by KIF11 or TRAF4 overexpression. Accordingly, the promotion of cell migration ability in the DR6-overexpression SKOV3 cells was rescued by KIF11 siRNA or TRAF4 siRNA (Fig. S2) knockdown (Fig. 4B). The expression of DR6, KIF11, and TRAF4 was evaluated in all the different experimental conditions shown in Figs S3 and S4. Furthermore, the migration-associated protein expression of PI3K/AKT and MAPK/ERK signaling pathways in the rescue experiment was also examined by western blot analysis. The results indicated that the expression variation of MMP2, MMP9, and E-cadherin induced by DR6 knockdown was also rescued by TRAF4 or KIF11 overexpression (Fig. 4C), and decreased activation of PI3K, p-AKT, and p-MEK with DR6 shRNA was rescued by TRAF4 or KIF11 overexpression (Fig. 4C). However, the activation of p-ERK was rescued by
KIF11 overexpression but not by TRAF4 overexpression; this indicated that TRAF4 might be partly involved in another signalling pathway transduced by MEK activation.

Furthermore, we compared the expression of KIF11 and TRAF4 with that of DR6 and found that the mRNA expression of KIF11 was correlated with DR6 expression in OVCA tissues (Fig. 5A; \( r = 0.4352, P < 0.01 \)). Additionally, TRAF4 mRNA expression was positively correlated with DR6 expression in the OVCA tissues (Fig. 5B; \( r = 0.3384, P < 0.01 \)). This concordant correlation of TRAF4 and KIF11 expression with that of DR6 suggested that a DR6–TRAF4–KIF11 complex may play an important role in OVCA migration.

**Discussion**

Although DR6 is expressed highly in many cancer types, its role and underlying molecular mechanisms in cancer progression remain unclear. It has been found previously that DR6 level in the serum increases in patients with late-stage OVCA [11]. Through analysis of TCGA database, we also identified DR6 overexpression in OVCA. Therefore, we aimed to investigate the function of DR6 in OVCA.

Several previous reports have shown that DR6 is closely associated with vascular endothelial cells. For instance, the number of microvessels expressing DR6 was obviously more in hens with early-stage OVCA than in hens with normal ovaries and was most in hens with late-stage OVCA [19]. Additionally, it was reported that DR6, as a confirmed tumor vascular marker, could also function as a serum biomarker in OVCA vasculature [11]. Tam et al. found in both zebrafish and mice that DR6 and TROY could regulate angiogenesis of the central nervous system. The interaction between DR6 and TROY was genetic and physical. And vascular endothelial growth factor mediated by c-Jun N-terminal kinase (JNK) activation was required for the interaction [5]. Strilic et al. reported that endothelial cell necroptosis induced by DR6 in tumor cells promoted cancer metastasis [12]. We also previously demonstrated that tumor angiogenesis of B16 required DR6, which was via the nuclear factor-kB, P38 MAPK, and signal transducer and activator of transcription 3 (STAT3) pathways [20]. Based on these reports, DR6 can be concluded to be vital in the function of endothelial cells. In this study, our data showed that DR6 enhanced ovarian carcinoma cell migration ability via the MAPK/ERK and PI3K/AKT pathways. Therefore, not only DR6 expressed on endothelial cells involved in cancer metastasis, but DR6 expression on cancer cells may also promote cancer metastasis.

To investigate the molecular signaling pathway of DR6 in cancer migration, a co-IP–MS strategy was...
conducted. KIF11 was confirmed to interact with DR6 by co-IP and GST pull-down assay. KIF11 is an important kinesin and exerts an obvious effect in the polarization of spindle apparatus in mitosis [21]. This may explain the overexpression of KIF11 in some tumors and leukemias compared with the normal sample [22,23]. The regulation of mitosis, migration, and intracellular transport by KIF11 occurs via interactions with microtubules [21,24,25]. Using MS analysis, a previous study identified that TRAF4 was an interacting protein of KIF11 [18]. The TRAF family was originally identified as a group of signal adaptors that interact directly with cytoplasmic parts of members of the TNF receptor superfamily. In human cancers, TRAF4 was overexpressed, and the gene was amplified [26–28]. Additionally, it was found that TRAF4 could enhance cell growth and migration in certain tumor cells [29,30]. Thus, we

Fig. 4. DR6 functions through its association with KIF11 and TRAF4. (A) Overexpression of KIF11 or TRAF4 reversed the DR6 knockdown-mediated reduction in SKOV3 cell migration. Scale bar = 200 μm. (B) Knocking down of KIF11 or TRAF4 reversed the DR6 overexpression-mediated increase in SKOV3 cell migration. Scale bar = 200 μm. (C) Western blot analysis of indicated protein expression in SKOV3 cells. Data are presented as mean ± SD (n = 8). **P < 0.01 (Student’s t test).
also determined the relationship between DR6 and TRAF4. As shown by our results, IP with an antibody developed against DR6 and IB with antibodies developed against TRAF4 and KIF11 indicated that TRAF4 and KIF11 co-immunoprecipitated with DR6 simultaneously; this co-IP suggests that a DR6–TRAF4–KIF11 complex may have a crucial function in OVCA migration. However, the formation of this protein complex requires further investigation. The differential effect of shTRAF4 and shKIF11 on p-ERK but not on MMP2, MMP9, or PI3K indicated that TRAF4 might be partly involved in other signal pathways transduced by MEK activation. MEK pathway is normally coupled to ERK. However, some studies showed that ERK could be activated without MEK activation. Simard et al. [31] showed that in human neutrophils stimulated with cytokines or Toll-like receptor ligands, MEK and ERK are activated independently of each other. This coupling of MEK and ERK was not observed. Aksamitiene et al. [32] confirmed the existence of a dynamic MEK-independent compensatory circuit for ERK activation in T47D cells that is induced by epidermal growth factor and other ligands of ErbB family receptors. MEK-independent ERK activation depends on PDZ-binding kinase/T-LAK-cell-originated protein kinase (PBK/TOPK). Consequently, the role of DR6 in OVCA related to the uncoupling of the MEK and ERK pathway will be addressed in our further research.

Conclusion

A novel function of DR6 in promoting cell migration was identified. The present discovery showed that DR6 has a significant effect on ovarian malignancy by interacting with TRAF4 and KIF11, and that targeting DR6 might be an important therapeutic strategy in the treatment of OVCA.

Acknowledgements

This work was supported by the Natural Science Foundation of China (grant number 81372200).

Author contributions

BS wrote the article and performed experiments. JB performed cell experiments. YL performed cell experiments. JS directed the project.

Conflict of interest

The authors declare no conflict of interest.

References

1. Pan G, Bauer JH, Haridas V, Wang S, Liu D, Yu G, Vincenz C, Aggarwal BB, Ni J and Dixit VM (1998) Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett 431, 351–356.

2. Guicciardi ME and Gores GJ (2009) Life and death by death receptors. FASEB J 23, 1625–1637.

3. Liu J, Na S, Glasebrook A, Fox N, Solenberg PJ, Zhang Q, Song HY and Yang DD (2001) Enhanced CD4+ T cell proliferation and Th2 cytokine production in DR6-deficient mice. Immunity 15, 23–34.

4. Hao H, Yan M, Wang H, Erickson S, Grewal IS and Dixit VM (2001) Impaired c-Jun amino terminal kinase activity and T cell differentiation in death receptor 6-deficient mice. J Exp Med 194, 1441–1448.

5. Tam SJ, Richmond DL, Kaminker JS, Modrusan Z, Martin-McNulty B, Cao TC, Weimer RM, Carano RA, van Bruggen N and Watts RJ (2012) Death receptors DR6 and TROY regulate brain vascular development. Dev Cell 22, 403–417.

6. Mi S, Lee X, Hu Y, Ji B, Shao Z, Yang W, Huang G, Walus L, Rhodes K, Gong BJ et al. (2011) Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination. Nat Med 17, 816–821.
Death receptor 6 promotes ovarian cancer cell migration

B. Shi et al.

7 Nikolaev A, McLaughlin T, O’Leary DD and Tessier-Lavigne M (2009) APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. *Nature* **457**, 981–989.

8 Huang G, Lee X, Bian Y, Shao Z, Sheng G, Pepinsky RB and Mi S (2013) Death receptor 6 (DR6) antagonist antibody is neuroprotective in the mouse SOD1G93A model of amyotrophic lateral sclerosis. *Cell Death Dis* **4**, e841.

9 Hu R, Du Q, Yin X, Li J, Wang T and Zhang L (2014) Agonist antibody activates death receptor 6 downstream signaling involving TRADD recruitment. *FEBS Lett* **588**, 401–407.

10 Kasof GM, Lu JJ, Liu D, Speer B, Mongan KN, Gomes BC and Lorenzi MV (2001) Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB. *Oncoogene* **20**, 7965–7975.

11 Sasaroli D, Gimotty PA, Pathak HB, Hammond R, Kougioumtzidou E, Katsaros D, Buckanovich R, Devarajan K, Sandaltzopoulos R, Godwin AK et al. (2011) Novel surface targets and serum biomarkers from the ovarian cancer vasculature. *Cancer Biol Therapy* **12**, 169–180.

12 Strilic B, Yang L, Albarrán-Juárez J, Wachsmuth L, Han K, Müller UC, Pasparakis M and Offermanns S (2016) Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis. *Nature* **11**, 215–218.

13 Serour GI (2010) A vision for FIGO 2009–2012. *Int J Gynaecol Obstet* **108**, 93–96.

14 Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res* **45**, W98–W102.

15 Hamidi A, Song J, Thakur N, Itoh S, Marcusson A, Bergh A, Heldin CH and Landström M (2017) TGF-β promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitylation of p85α. *Sci Signal* **10**, 486.

16 Xue G and Hemmings BA (2013) PKB/Akt-dependent regulation of cell motility. *J Natl Cancer Inst* **105**, 393–404.

17 Dhillon AS, Hagan S, Rath O and Kolch W (2007) MAP kinase signalling pathways in cancer. *Oncoogene* **26**, 3279–3290.

18 Wojciech EJ, Buckley RS, Richard J, Liu L, Huckaba TM and Kim S (2013) Kinesin-5: cross-bridging mechanism to targeted clinical therapy. *Gene* **531**, 133–149.

19 Barua A, Yellapa A, Bahr JM, Abramowicz JS, Edassembly SL, Basu S, Rotmensch J and Bitterman P (2012) Expression of death receptor 6 by ovarian tumors in laying hens, a preclinical model of spontaneous ovarian cancer. *Transl Oncol* **5**, 260–268.

20 Yang X, Shi B, Li L, Xu Z, Ge Y, Shi J, Liu Y and Zheng D (2016) Death receptor 6 (DR6) is required for mouse B16 tumor angiogenesis via the NF-kappaB, P38 MAPK and STAT3 pathways. *Oncoogenesis* **5**, e206.

21 Rath O and Koziel F (2012) Kinesins and cancer. *Nat Rev Cancer* **12**, 527–539.

22 Carter BZ, Mak DH, Shi Y, Schober WD, Wang RY, Konopleva M, Koller E, Dean NM and Andreff M (2006) Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. *Cell Cycle* **5**, 2223–2229.

23 Infante JR, Patnaik A, Verschraegen CF, Olzsianski AJ, Shaheen M, Burris HA, Tolcher AW, Papadopoulos KP, Beeram M, Hynes SM et al. (2017) Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer. *Cancer ChemotherPharmacol* **79**, 315–326.

24 Falnikar A, Tole S and Baas PW (2011) Kinesin-5, a mitotic microtubule-associated motor protein, modulates neuronal migration. *Mol Biol Cell* **22**, 1561–1574.

25 Sun XD, Shi XJ, Sun XO, Luo YG, Wu XJ, Yao CF, Yu HY, Li DW, Liu M and Zhou J (2011) Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5. *Acta Pharmacol Sin* **32**, 1543–1548.

26 Camilleri-Broët S, Cremer I, Marmey B, Comperat E, Vigué F, Audouin J, Rio MC, Fridman WH, Sautès-Fridman C and Régnier CH (2007) TRAF4 overexpression is a common characteristic of human carcinomas. *Oncoogene* **26**, 142–147.

27 Zhao ZJ, Ren HY, Yang F, Wang J, Wu GP and Mi XY (2015) Expression, correlation, and prognostic value of TRAF2 and TRAF4 expression in malignant plural effusion cells in human breast cancer. *DiagnCytopathol* **43**, 897–903.

28 Liu K, Wu X, Zang X, Huang Z, Lin Z, Tan W, Wu X, Hu W, Li B and Zhang L (2017) TRAF4 regulates migration, invasion, and epithelial-mesenchymal transition via PI3K/AKT signaling in hepatocellular carcinoma. *Oncol Res* **25**, 1329–1340.

29 Li W, Peng C, Lee MH, Lim D, Zhu F, Fu Y, Yang G, Sheng Y, Xiao L, Dong X et al. (2013) TRAF4 is a critical molecule for Akt activation in lung cancer. *Cancer Res* **73**, 6938–6950.

30 Zhang L, Zhou F, García de Vinuesa A, de Kruijf EM, Mesker WE, Hui L, Drabsch Y, Li Y, Bauer A, Rousseau A et al. (2013) TRAF4 promotes TGF-beta receptor signaling and drives breast cancer metastasis. *Mol Cell* **51**, 559–572.

31 Simard FA, Cloutier A, Ear T, Vardhan H and McDonald PP (2015) MEK-independent ERK activation in human neutrophils and its impact on functional responses. *J Leukoc Biol* **98**, 565–573.

32 Aksamitiene E, Kholodenko BN, Kolch W, Hoek JB and Kiyatkin A (2010) PI3K/Akt-sensitive MEK-
independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
*Cell Signal* 22, 1369–1378.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Fig. S1.** Western blot analysis of expression of indicated proteins in SKOV3 cells transfected with pcDNA3.1-KIF11 or pcDNA3.1-TRAF4.

**Fig. S2.** Western blot analysis of expression of indicated proteins in SKOV3 cells transfected with KIF11 siRNA or TRAF4 siRNA.

**Figs S3 and S4.** The expression of DR6, KIF11 and TRAF4 evaluated in all the different experimental conditions.